The PSA Test


What is Prostate Specific Antigen (PSA)?

Prostate Specific Antigen (PSA) is a protein produced within the prostate gland and is secreted into seminal fluid.

There are two types of PSA:
  1. Free PSA: moves freely in the blood as it is unbound to other proteins  
  2. Complex PSA: attached to other proteins as it moves around the blood
Free PSA comes from benign prostatic hyperplasia (BPH), an enlargement of the prostate. The higher the amount of free PSA, the less likely prostate cancer will be found as prostate cancer cells produce more complex PSA.


What is the PSA test?

The PSA test is a simple blood test, taken from the arm, which measures the amount of PSA protein in the blood. It is common for PSA to be found in the blood in very small concentrations. Higher levels of PSA may indicate the presence of cancer, but can also be an indicator of other prostate conditions.
PSA_Test.png
Prostate Cancer Canada graciously acknowledges the Princess Margaret Cancer Centre for sharing this image with us.
What are the benefits and limitations of the PSA test?
 
Benefits Limitations
May indicate the presence of cancer in its earliest stages. May lead to unnecessary tests and treatment.
Simple blood test (not harmful). Cannot distinguish between slow growing and advanced cancer.
Currently only test we have as red flag to indicate follow-up. The PSA test cannot diagnose prostate cancer but can tell you if there’s a problem with the prostate.


Prostate Cancer Canada recommends that men in their 40s get a PSA test to establish their baseline. Men who have elevated risk factors should talk with their healthcare provider about prostate cancer before the age of 40.

It's important to note that the PSA test is often used to monitor how someone responds to cancer treatment or to monitor disease recurrence or progression.


RELEVANT LINKS

News Release: Prostate Cancer Canada reminds men that early detection using ‘Smart Screening’ for prostate cancer can save lives
SupportPSATests.ca
PCC's Position Paper on PSA Testing
PCC's PSA Recommendation: News Release
Infographic: Know Your Number
Infographic: What Affects PSA Values

For more information and support:





Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
BRCA2 gene implicated in rare but lethal prostate cancer

January 9, 2017 – TORONTO, ON – Canadian scientists have discovered a link between an inherited mutation in the BRCA2 gene and a deadly form of prostate cancer.
More

Scientists identify DNA signature linked to prostate cancer severity

January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature.
More

Thank You to our Canadian Mo Bros and Sistas!

TORONTO, December 1, 2016 - Prostate Cancer Canada congratulates the more than 500,000 Mo Bros and Mo Sistas worldwide who participated in this year's Movember campaign.
More


Click here for news archive